Form 4: Recursion Pharmaceuticals Director Trades Class A Stock

Director Christopher Gibson of Recursion Pharmaceuticals reported a transaction involving Class A Common Stock, executed under a Rule 10b5-1 trading plan.

Summary

• Director Christopher Gibson of Recursion Pharmaceuticals, Inc. (RXRX) engaged in a transaction on May 22, 2026.
• This transaction involved the disposition of 40,000 shares of Class A Common Stock at a price of $3.08 per share.
• The disposition was part of a Rule 10b5-1 trading plan adopted by Mr. Gibson on May 12, 2025.
• Concurrently, 40,000 shares of Class B Common Stock were automatically converted into Class A Common Stock, with no change in beneficial ownership reported for these converted shares.
• Following these transactions, Mr. Gibson's direct beneficial ownership of Class A Common Stock is reported as 883,735 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction was conducted under a pre-established 10b5-1 plan, mitigating concerns about opportunistic insider trading, though any sale by a director warrants attention.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and orderly disposition of shares rather than a reaction to immediate market conditions.
• The conversion of Class B Common Stock to Class A Common Stock is a standard procedural event and does not represent a new sale or divestment of underlying value.

Negatives

• A disposition of 40,000 shares of Class A Common Stock at $3.08 per share indicates a sale of company stock by a director.

Risks

• While executed under a 10b5-1 plan, any significant stock sale by a director can be perceived negatively by the market, potentially impacting investor sentiment.
• The specific price of $3.08 per share may reflect market conditions at the time of the transaction, but a sale at this price could be viewed as a loss compared to historical or potential future valuations.

Future Outlook

This filing is a report of past transactions and does not contain forward-looking statements or guidance from the company.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by directors is common practice to diversify holdings or manage personal finances in a way that avoids accusations of insider trading, as it establishes a pre-determined schedule or price for trades.

Stakeholder Impact

• Shareholders may view the sale of stock by a director with caution, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Recursion Pharmaceuticals, RXRX, Director Transaction, Stock Sale, Class A Common Stock, Class B Common Stock, Beneficial Ownership